Manta Pharma LLC develops an AI‑powered Active Implantable Medical Device (AIMD) that combines a temperature‑stable drug formulation, an intelligent micro‑pump, and a biosensor, all coordinated by an AI engine that autonomously adjusts dosing in real time. The closed‑loop, subcutaneous implant delivers precise, safe medication for chronic conditions such as diabetes, autoimmune diseases, substance use disorders, and HIV/AIDS, improving adherence across home, clinical, and high‑stress environments.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with chronic diseases often struggle with medication adherence, leading to suboptimal therapeutic outcomes and increased healthcare costs. Traditional delivery methods lack real-time dose adjustment and may be unsuitable for patients in remote, high‑stress, or institutional settings.
Solution
Manta Pharma has created an AI‑powered Active Implantable Medical Device (AIMD) that autonomously administers drugs subcutaneously. The platform combines a temperature‑stable formulation, an intelligent micro‑pump, and an integrated biosensor, all coordinated by an AI engine that continuously monitors physiological signals and adjusts dosing in real time. This closed‑loop system provides precise, safe delivery without patient intervention, supporting both home‑based care and use in hospitals, hospices, or demanding environments such as military deployments. By maintaining therapeutic drug levels automatically, the device aims to improve adherence and clinical outcomes across a wide range of chronic conditions.
Target Audience
Primary customers are pharmaceutical companies and medical device manufacturers seeking an autonomous delivery platform for chronic‑therapy drugs, as well as healthcare providers managing patients with adherence‑sensitive conditions.
Features
- Temperature‑stable drug formulation that remains effective across the body’s temperature range
- Miniaturized micro‑pump capable of precise, programmable infusion rates
- Integrated biosensor suite that continuously measures relevant biomarkers for dose titration
- AI “autopilot” engine that processes sensor data and dynamically adjusts drug delivery in real time
- Fully subcutaneous, implantable design enabling long‑term autonomous operation without external equipment
- Broad therapeutic applicability covering autoimmune diseases, diabetes, substance use disorders, HIV/AIDS, cardiovascular, respiratory, CNS, pain, cancer, and neurodegenerative conditions